JP2022541911A5 - - Google Patents

Info

Publication number
JP2022541911A5
JP2022541911A5 JP2022503918A JP2022503918A JP2022541911A5 JP 2022541911 A5 JP2022541911 A5 JP 2022541911A5 JP 2022503918 A JP2022503918 A JP 2022503918A JP 2022503918 A JP2022503918 A JP 2022503918A JP 2022541911 A5 JP2022541911 A5 JP 2022541911A5
Authority
JP
Japan
Prior art keywords
carrier protein
amino acid
modified carrier
derived
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022503918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541911A (ja
Filing date
Publication date
Priority claimed from EP19187963.4A external-priority patent/EP3770269A1/en
Application filed filed Critical
Publication of JP2022541911A publication Critical patent/JP2022541911A/ja
Publication of JP2022541911A5 publication Critical patent/JP2022541911A5/ja
Pending legal-status Critical Current

Links

JP2022503918A 2019-07-23 2020-07-21 バイオコンジュゲートグリコシル化の定量化 Pending JP2022541911A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19187963.4A EP3770269A1 (en) 2019-07-23 2019-07-23 Quantification of bioconjugate glycosylation
EP19187963.4 2019-07-23
PCT/EP2020/070595 WO2021013854A1 (en) 2019-07-23 2020-07-21 Quantification of bioconjugate glycosylation

Publications (2)

Publication Number Publication Date
JP2022541911A JP2022541911A (ja) 2022-09-28
JP2022541911A5 true JP2022541911A5 (cg-RX-API-DMAC7.html) 2023-07-07

Family

ID=67438602

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022503918A Pending JP2022541911A (ja) 2019-07-23 2020-07-21 バイオコンジュゲートグリコシル化の定量化

Country Status (8)

Country Link
US (1) US20220257751A1 (cg-RX-API-DMAC7.html)
EP (2) EP3770269A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022541911A (cg-RX-API-DMAC7.html)
CN (1) CN114302890A (cg-RX-API-DMAC7.html)
BR (1) BR112022001034A2 (cg-RX-API-DMAC7.html)
CA (1) CA3147700A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022000880A (cg-RX-API-DMAC7.html)
WO (1) WO2021013854A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022083585A1 (zh) * 2020-10-20 2022-04-28 上海瑞宙生物科技有限公司 一种蛋白多糖结合物及其应用
EP4409035A4 (en) * 2021-09-30 2026-01-07 Venn Biosciences Corp SYSTEMS AND METHODS FOR DETERMINING GLYCOPEPTIDE CONCENTRATION, DETERMINING STANDARDIZED ABUNDANCE, AND PREPARING SAMPLES FOR LC/MS
WO2025172892A1 (en) * 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
DK1481057T3 (da) 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
ES2535084T3 (es) 2005-05-11 2015-05-05 Eth Zurich Proteínas N-glicosiladas recombinantes procedentes de células procariotas
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
SI2257307T1 (sl) 2008-02-20 2018-09-28 Glaxosmithkline Biologicals S.A. Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic
US20110189223A1 (en) 2008-04-16 2011-08-04 Glaxosmithkline Biologicals S.A. Vaccine
KR20110009157A (ko) 2008-04-16 2011-01-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
JP2012533285A (ja) 2009-07-17 2012-12-27 オーシャン ハーベスト テクノロジー (カナダ) インコーポレイテッド 魚用飼料中の合成添加物を置換する、天然かつ持続可能な海藻配合物
NO2501406T3 (cg-RX-API-DMAC7.html) 2009-11-19 2018-05-19
WO2011138361A1 (en) 2010-05-06 2011-11-10 Glycovaxyn Capsular gram-positive bacteria bioconjugate vaccines
CA2847621A1 (en) * 2011-09-06 2013-03-14 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
WO2014037585A1 (en) 2012-09-10 2014-03-13 Glycovaxyn Ag Bioconjugates comprising modified antigens and uses thereof
KR20150068998A (ko) 2012-10-12 2015-06-22 글리코박신 아게 숙주 세포 변형 방법
EP2917351B1 (en) 2012-11-07 2018-12-19 GlaxoSmithKline Biologicals S.A. Production of recombinant vaccine in e. coli by enzymatic conjugation
AR104469A1 (es) 2014-08-08 2017-07-26 Glycovaxyn Ag Células huésped modificadas para su uso en producción de bioconjugados
SI3240895T1 (sl) 2014-12-30 2022-04-29 Glaxosmithkline Biologicals S.A. Sestavki in postopki za glikozilacijo proteinov
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions

Similar Documents

Publication Publication Date Title
US20240100140A1 (en) Immunogenic composition
Maleki Kakelar et al. Pathogenicity of Helicobacter pylori in cancer development and impacts of vaccination
US20190282682A1 (en) Modified host cells and hybrid oligosaccharides for use in bioconjugate production
CN113950524B (zh) 生产大肠杆菌o-抗原多糖的生物缀合物的方法、其组合物及其使用方法
JP6682451B2 (ja) 改変型宿主細胞およびその使用
JP2019030309A (ja) 酵素的コンジュゲート化による大腸菌での組み換えワクチンの製造
US11406696B2 (en) P aeruginosa PcrV-linked antigen vaccines
CN113924112A (zh) 大肠杆菌o-抗原多糖的生物缀合物、其生产方法及其使用方法
CN106535927A (zh) 新颖多糖及其用途
CN115803087B (zh) 多价疫苗组合物及其用途
US12128096B2 (en) Immunogenic composition
Fox et al. Novel lipopolysaccharide biosynthetic genes containing tetranucleotide repeats in Haemophilus influenzae, identification of a gene for adding O‐acetyl groups
AU2012306345A1 (en) Bioconjugate vaccines made in prokaryotic cells
WO2006065137A2 (en) Novel efficient production process for capsular polysaccharides of pathogenic grampositive bacteria by heterologous expression and secretion of complex polysaccharides in non-pathogenic, non-invasive gram- positive bacteria
Skurnik Molecular genetics, biochemistry and biological role of Yersinia lipopolysaccharide
TW202304504A (zh) 大腸桿菌o18生物軛合物之生產
Chaffin et al. CpsK of Streptococcus agalactiae exhibits α2, 3‐sialyltransferase activity in Haemophilus ducreyi
US20240139304A1 (en) P aeruginosa pcrv-linked antigen vaccines
JP2023530154A5 (cg-RX-API-DMAC7.html)
EA047805B1 (ru) Получение биоконъюгатов e.coli o18
Oldfield The genetic basis of lipopolysaccharide biosynthesis in Campylobacter jejuni
Jankovic Characterisation of the lex2B gene and its role in LPS biosynthesis in Campylobacter jejuni